What to Expect at the World Cell & Gene Therapy Summit South Korea
행사 소개
South Korea’s cell and gene therapy landscape is highly dynamic, as observed from regulatory approvals, clinical trial progress, and manufacturing activity, from over 150 companies in active drug development. Additionally, with global pharma including Bayer, Novartis and more seeing strategic investments into the CGT space within South Korea, greater opportunities for scientific innovation and technology advancement are yet to come.
The inaugural World Cell & Gene Therapy Summit South Korea is an exclusive opportunity to connect with global pharma and leading Korean biotech showcasing the latest trends in autologous, allogeneic, in vivo, and gene editing therapies to help you identify gaps within your programs and set the roadmap of CGT development in 2026/2027.
Join 80+ world-class international experts including T-Knife Therapeutics, Bionoxx, Byterna Therapeutics and more, to progress early proof-of-concept CAR-TCR, genome editing and RNA-based cell and gene therapies to patients faster.
This event is part of the World Advanced Therapeutics Summit South Korea by Hanson Wade, so attendees will also have access to sessions for the 2nd World RNA-Based Therapeutics & Vaccines Summit South Korea.
Unmissable Event Highlights
놓칠 수 없는 행사 하이라이트
Boost your R&D innovations from in vivo CAR, dual and triple-targeted engineering to gene editing breakthroughs to achieve clinical validation for oncology and autoimmune patients with insights from Caribou Biosciences, T-Knife Therapeutics, and Genome Frontier Therapeutics
Unearth key biological mechanisms of action data from across T-, NK-, macrophage and stem cell modalities to achieve effective tumor targeting with insights from iPS Bio, VaxCell Bio, and KW-Bio
Optimize your cargo delivery for in vivo CAR and gene editing programs with LNP platforms to achieve targeted specificity with insights from Byterna Therapeutics, and GC Biopharma
Overcome global and South Korean supply and manufacturing challenges for autologous and allogenic approaches to ensure consistency and scalability at GMP level with insights from Genentech, Curocell, and UWELL Biopharma
Explore the Full Event Guide
공식 아젠다를 다운로드하여 다음 내용을 확인하세요:
- Discover, produce, and accelerate CGT to reduce time to patient care
- Gain insights from 20+ Korean-based and international speakers
- Dive into 20+ data driven case-studies from pre-clinical research to GMP commercial
- Engage in unrivalled networking opportunities from experts across cell, gene and RNA therapy fields
Who Will You Meet?
참석 기업
This is your opportunity to connect and collaborate with international and local Korean biotech, pharma and key solution experts from C-Suite to Scientist to build new alliances through strategic discussions and work together to advance Korean CGT medicines to patients faster.
What Your Peers Have to Say
The future of cell and gene therapy will be shaped by the convergence of programmable RNA medicines, targeted delivery, and in vivo cell engineering. The World Cell & Gene Therapy Summit South Korea provides a valuable platform for global leaders to exchange ideas on how to accelerate clinical translation, improve manufacturing efficiency, and expand patient access across oncology, autoimmune diseases, and beyond. We are pleased to take part in this important dialogue and contribute Byterna’s perspective as an circular mRNA therapeutics company advancing circular mRNA-based in vivo CAR-T programs
Xian Zeng, Chief Executive Officer, Byterna Therapeutics
The World Cell & Gene Therapy Summit South Korea provides an important platform to connect scientific innovation, clinical translation, manufacturing strategy, and investment perspectives in the rapidly evolving cell and gene therapy field. As iPSC-derived therapies move closer to clinical application, meetings like this are highly valuable for fostering practical dialogue among innovators, clinicians, regulators, manufacturers, and industry partners. iPS Bio is pleased to contribute to this discussion by sharing our experience in developing iPSC-based therapeutic approaches for neurodegenerative diseases
Jihwan Song, Founder & Chief Technology Officer, iPS Bio
Explore the Agenda
Hear the latest technology innovations taking place within South Korea and gain exclusive insights on the progress in development globally.
Partner With Us
Position yourself alongside other leading solution providers to ensure your company is the go-to service providers for Korean Advanced Therapeutics leaders.
Join Biopharma Experts
Be part of the hottest conversations with like-minded scientists, C-level executives, heads, managers, VPs, and more across discovery, clinical and CMC functions.